» Articles » PMID: 20403078

Nature and Cause of Mitochondrial Dysfunction in Huntington's Disease: Focusing on Huntingtin and the Striatum

Overview
Journal J Neurochem
Specialties Chemistry
Neurology
Date 2010 Apr 21
PMID 20403078
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Polyglutamine expansion mutation in huntingtin causes Huntington's disease (HD). How mutant huntingtin (mHtt) preferentially kills striatal neurons remains unknown. The link between mitochondrial dysfunction and HD pathogenesis stemmed from postmortem brain data and mitochondrial toxin models. Current evidence from genetic models, containing mHtt, supports mitochondrial dysfunction with yet uncertain nature and cause. Because mitochondria composition and function varies across tissues and cell-types, mitochondrial dysfunction in HD vulnerable striatal neurons may have distinctive features. This review focuses on mHtt and the striatum, integrating experimental evidence from patients, mice, primary cultures and striatal cell-lines. I address the nature (specific deficits) and cause (mechanisms linked to mHtt) of HD mitochondrial dysfunction, considering limitations of isolated vs. in situ mitochondria approaches, and the complications introduced by glia and glycolysis in brain and cell-culture studies. Current evidence relegates respiratory chain impairment to a late secondary event. Upstream events include defective mitochondrial calcium handling, ATP production and trafficking. Also, transcription abnormalities affecting mitochondria composition, reduced mitochondria trafficking to synapses, and direct interference with mitochondrial structures enriched in striatal neurons, are possible mechanisms by which mHtt amplifies striatal vulnerability. Insights from common neurodegenerative disorders with selective vulnerability and mitochondrial dysfunction (Alzheimer's and Parkinson's diseases) are also addressed.

Citing Articles

Influence of dietary patterns in the pathophysiology of Huntington's Disease: A literature review.

Ansari U, Nadora D, Alam M, Wen J, Asad S, Lui F AIMS Neurosci. 2024; 11(2):63-75.

PMID: 38988882 PMC: 11230857. DOI: 10.3934/Neuroscience.2024005.


Disruption of the mitochondrial network in a mouse model of Huntington's disease visualized by in-tissue multiscale 3D electron microscopy.

Martin-Solana E, Casado-Zueras L, Torres T, Goya G, Fernandez-Fernandez M, Fernandez J Acta Neuropathol Commun. 2024; 12(1):88.

PMID: 38840253 PMC: 11151585. DOI: 10.1186/s40478-024-01802-2.


Elucidating the Influence of Lipid Composition on Bilayer Perturbations Induced by the N-terminal Region of the Huntingtin Protein.

Gamage Y, Pan J Biophysica. 2024; 3(4):582-597.

PMID: 38737720 PMC: 11087071. DOI: 10.3390/biophysica3040040.


Mitochondrial Inherited Disorders and their Correlation with Neurodegenerative Diseases.

Gushi S, Balis V Endocr Metab Immune Disord Drug Targets. 2023; 24(4):381-393.

PMID: 37937560 DOI: 10.2174/0118715303250271231018103202.


Mitochondrial Dysfunction as a Signaling Target for Therapeutic Intervention in Major Neurodegenerative Disease.

Mangrulkar S, Wankhede N, Kale M, Upaganlawar A, Taksande B, Umekar M Neurotox Res. 2023; 41(6):708-729.

PMID: 37162686 DOI: 10.1007/s12640-023-00647-2.